[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-001", "question": "A 45-year-old man with a history of alcoholic cirrhosis presents to the ICU with massive upper gastrointestinal bleeding. Despite endoscopic intervention and octreotide infusion, bleeding persists, and he develops hemodynamic instability. Transjugular intrahepatic portosystemic shunt (TIPS) is considered, but imaging reveals a rare anatomical variant. What is the most appropriate next step in management?", "options": ["Proceed with TIPS using a covered stent to mitigate risks", "Initiate balloon tamponade with a Sengstaken-Blakemore tube", "Administer terlipressin as an alternative vasoconstrictor", "Perform urgent surgical portocaval shunt", "Refer for angiographic embolization of the coronary vein"], "answer": "E", "answer_index": 4, "explanation": "In persistent variceal bleeding with anatomical variants precluding TIPS, angiographic embolization targets specific bleeding vessels like the coronary vein, offering a less invasive option. TIPS is contraindicated due to the variant, while surgical shunts carry high mortality in unstable patients. Terlipressin and balloon tamponade are temporizing but not definitive here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (multiple answers defensible; secondary U, underspecified). Verdict on keyed answer: Not uniquely determinable. The clinical problem is determining the next management step for persistent upper GI bleeding in a cirrhotic patient with hemodynamic instability when a rare anatomical variant complicates TIPS consideration. Key stem clues: alcoholic cirrhosis, massive UGIB refractory to endoscopy and octreotide, instability, unspecified rare anatomical variant on imaging—these imply refractory variceal bleeding but fail to drive a unique best answer due to vagueness on the variant's impact. Most likely diagnosis: refractory esophageal or gastric varices. Keyed answer E (angiographic embolization) fits as a less invasive definitive option if TIPS is precluded, assuming the variant contraindicates it. Alternatives: A is worse if variant precludes TIPS but defensible if navigable with covered stent; B is temporizing for instability but not definitive; C adds another vasoconstrictor redundantly to octreotide; D is high-risk surgery in unstable patient. Main logical issue: stem's unspecified variant requires unstated assumption that it contraindicates TIPS, allowing A, B, or E as equally defensible based on interpretation. Main medical accuracy issues: none major; aligns with guidelines (e.g., AASLD) where embolization is viable for refractory varices when TIPS infeasible, though terlipressin availability varies regionally. Minimal fix: Edit stem to specify 'imaging reveals portal vein agenesis contraindicating TIPS.'\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible; secondary U, underspecified). Verdict on keyed answer: Not uniquely determinable. The clinical problem is determining the next management step for persistent upper GI bleeding in a cirrhotic patient with hemodynamic instability when a rare anatomical variant complicates TIPS consideration. Key stem clues: alcoholic cirrhosis, massive UGIB refractory to endoscopy and octreotide, instability, unspecified rare anatomical variant on imaging—these imply refractory variceal bleeding but fail to drive a unique best answer due to vagueness on the variant's impact. Most likely diagnosis: refractory esophageal or gastric varices. Keyed answer E (angiographic embolization) fits as a less invasive definitive option if TIPS is precluded, assuming the variant contraindicates it. Alternatives: A is worse if variant precludes TIPS but defensible if navigable with covered stent; B is temporizing for instability but not definitive; C adds another vasoconstrictor redundantly to octreotide; D is high-risk surgery in unstable patient. Main logical issue: stem's unspecified variant requires unstated assumption that it contraindicates TIPS, allowing A, B, or E as equally defensible based on interpretation. Main medical accuracy issues: none major; aligns with guidelines (e.g., AASLD) where embolization is viable for refractory varices when TIPS infeasible, though terlipressin availability varies regionally. Minimal fix: Edit stem to specify 'imaging reveals portal vein agenesis contraindicating TIPS.'", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-002", "question": "A 62-year-old woman with metastatic breast cancer on paclitaxel develops acute dyspnea and hypoxemia. CT angiography shows no pulmonary embolism, but echocardiography reveals right ventricular strain. Bone marrow biopsy confirms tumor infiltration. What is the most likely diagnosis?", "options": ["Paclitaxel-induced pneumonitis", "Tumor microembolism syndrome", "Lymphangitic carcinomatosis", "Chemotherapy-associated pulmonary veno-occlusive disease", "Metastatic tumor thrombus in pulmonary arteries"], "answer": "B", "answer_index": 1, "explanation": "Tumor microembolism syndrome occurs when tumor cells embolize to pulmonary vasculature, causing right heart strain without macroscopic emboli, fitting this presentation in metastatic cancer. Lymphangitic carcinomatosis typically shows interstitial patterns on imaging, while paclitaxel pneumonitis is inflammatory. Veno-occlusive disease is more associated with stem cell transplant regimens.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute dyspnea and hypoxemia in a patient with metastatic breast cancer on paclitaxel, absence of pulmonary embolism on CT angiography, right ventricular strain on echocardiography, and bone marrow biopsy confirming tumor infiltration. These findings point to microscopic tumor emboli causing pulmonary vascular obstruction and right heart strain without macroscopic clots. The clinical problem asks for the most likely diagnosis explaining this presentation. Discriminating findings: no PE rules out macroscopic thrombi (E); RV strain suggests pulmonary vascular involvement; bone marrow infiltration supports tumor cell embolization (B). Keyed answer B (Tumor microembolism syndrome) fits as it describes tumor cells embolizing to pulmonary arterioles, leading to hypoxemia and RV strain in metastatic disease. Alternatives: A (Paclitaxel-induced pneumonitis) is inflammatory, lacks RV strain; C (Lymphangitic carcinomatosis) shows interstitial imaging patterns, not acute RV strain; D (Chemotherapy-associated pulmonary veno-occlusive disease) is linked to different regimens; E (Metastatic tumor thrombus) would appear on CTA. Main logical issue(s): None; stem allows discrimination without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current understanding of tumor microembolism in cancers like breast, causing cor pulmonale-like syndrome. Minimal fix: None needed, item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include acute dyspnea and hypoxemia in a patient with metastatic breast cancer on paclitaxel, absence of pulmonary embolism on CT angiography, right ventricular strain on echocardiography, and bone marrow biopsy confirming tumor infiltration. These findings point to microscopic tumor emboli causing pulmonary vascular obstruction and right heart strain without macroscopic clots. The clinical problem asks for the most likely diagnosis explaining this presentation. Discriminating findings: no PE rules out macroscopic thrombi (E); RV strain suggests pulmonary vascular involvement; bone marrow infiltration supports tumor cell embolization (B). Keyed answer B (Tumor microembolism syndrome) fits as it describes tumor cells embolizing to pulmonary arterioles, leading to hypoxemia and RV strain in metastatic disease. Alternatives: A (Paclitaxel-induced pneumonitis) is inflammatory, lacks RV strain; C (Lymphangitic carcinomatosis) shows interstitial imaging patterns, not acute RV strain; D (Chemotherapy-associated pulmonary veno-occlusive disease) is linked to different regimens; E (Metastatic tumor thrombus) would appear on CTA. Main logical issue(s): None; stem allows discrimination without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current understanding of tumor microembolism in cancers like breast, causing cor pulmonale-like syndrome. Minimal fix: None needed, item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-003", "question": "A 28-year-old man presents to the emergency department with severe headache, vomiting, and photophobia after a recent hiking trip. CSF analysis shows lymphocytic pleocytosis, elevated protein, and normal glucose. PCR for common viruses is negative, but serology reveals antibodies to a rare pathogen. What is the most appropriate initial management?", "options": ["Intravenous acyclovir for presumed herpes encephalitis", "Empiric antibiotics for bacterial meningitis", "Supportive care with close monitoring", "Corticosteroids to reduce inflammation", "Antifungal therapy targeting endemic mycoses"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests lymphocytic meningitis from a rare arbovirus like Jamestown Canyon virus, where supportive care is the mainstay as no specific antiviral exists. Acyclovir is for herpes, unnecessary here with negative PCR. Antibiotics are for bacterial etiologies, ruled out by CSF profile.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: Post-hiking exposure, symptoms of severe headache, vomiting, photophobia; CSF with lymphocytic pleocytosis, elevated protein, normal glucose; negative PCR for common viruses; positive serology for unspecified rare pathogen. These suggest aseptic meningitis, likely viral or atypical bacterial, but fail to drive a unique best due to ambiguity in pathogen identity—could be untreatable arbovirus (favoring C) or treatable tick-borne bacterial like Lyme (favoring B). Main logical issue(s): Multiple answers defensible (M) as stem allows reasonable arguments for supportive care (C) or antibiotics (B) depending on interpretation of 'rare pathogen'; underspecified (U) by not naming the pathogen, requiring unstated assumptions for discrimination. Main medical accuracy issue(s): Intended logic for arboviral meningitis with supportive care aligns with standards (e.g., no specific therapy for Jamestown Canyon virus), but stem's vagueness permits accurate alternatives like Lyme disease management with antibiotics, introducing minor clinical unrealism without contradicting consensus. Minimal fix: Edit stem to specify 'serology reveals antibodies to Jamestown Canyon virus' to unambiguously support C as unique best.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. Key stem clues that drive (or fail to drive) a unique best answer: Post-hiking exposure, symptoms of severe headache, vomiting, photophobia; CSF with lymphocytic pleocytosis, elevated protein, normal glucose; negative PCR for common viruses; positive serology for unspecified rare pathogen. These suggest aseptic meningitis, likely viral or atypical bacterial, but fail to drive a unique best due to ambiguity in pathogen identity—could be untreatable arbovirus (favoring C) or treatable tick-borne bacterial like Lyme (favoring B). Main logical issue(s): Multiple answers defensible (M) as stem allows reasonable arguments for supportive care (C) or antibiotics (B) depending on interpretation of 'rare pathogen'; underspecified (U) by not naming the pathogen, requiring unstated assumptions for discrimination. Main medical accuracy issue(s): Intended logic for arboviral meningitis with supportive care aligns with standards (e.g., no specific therapy for Jamestown Canyon virus), but stem's vagueness permits accurate alternatives like Lyme disease management with antibiotics, introducing minor clinical unrealism without contradicting consensus. Minimal fix: Edit stem to specify 'serology reveals antibodies to Jamestown Canyon virus' to unambiguously support C as unique best.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-004", "question": "A 7-year-old boy with autism spectrum disorder presents with recurrent episodes of staring spells and facial twitching. EEG shows multifocal epileptiform discharges, and MRI reveals subtle cortical dysplasia. Genetic testing identifies a de novo mutation. What is the most effective first-line therapy?", "options": ["Valproic acid for broad-spectrum coverage", "Levetiracetam to minimize behavioral side effects", "Carbamazepine for focal seizures", "Vagus nerve stimulation as adjunct", "Ketogenic diet initiation"], "answer": "B", "answer_index": 1, "explanation": "In epileptic encephalopathy due to mutations like SCN8A, levetiracetam is preferred for its efficacy and lower risk of exacerbating behavioral issues in autism. Valproic acid can worsen aggression, while carbamazepine may aggravate generalized features. Dietary therapies are second-line.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (secondary M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 7-year-old with ASD, staring spells and facial twitching (suggesting seizures), multifocal EEG discharges, subtle cortical dysplasia, unspecified de novo mutation; these imply genetic epileptic encephalopathy but lack gene specificity to guide therapy uniquely. Main logical issue(s): Underspecified due to missing gene details (e.g., SCN8A vs. others), requiring unstated assumptions to select B over A or C; this leads to multiple defensible answers (e.g., A for broad coverage in multifocal epilepsy, B for ASD behavioral tolerance, C for focal features). Main medical accuracy issue(s): Rationale assumes SCN8A-like mutation where levetiracetam is preferred, but this is not universally accurate— for SCN8A, sodium channel blockers like carbamazepine (C) are often effective first-line; valproic acid (A) risks behavioral worsening in ASD, consistent with guidelines, but item's implied logic overlooks gene-specific nuances and regional variations in therapy. Overall, vignette aligns with board-level epilepsy management but introduces inaccuracy by not specifying mutation. Minimal fix: Edit stem to specify 'de novo SCN8A mutation' to make B uniquely defensible and accurate.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (secondary M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 7-year-old with ASD, staring spells and facial twitching (suggesting seizures), multifocal EEG discharges, subtle cortical dysplasia, unspecified de novo mutation; these imply genetic epileptic encephalopathy but lack gene specificity to guide therapy uniquely. Main logical issue(s): Underspecified due to missing gene details (e.g., SCN8A vs. others), requiring unstated assumptions to select B over A or C; this leads to multiple defensible answers (e.g., A for broad coverage in multifocal epilepsy, B for ASD behavioral tolerance, C for focal features). Main medical accuracy issue(s): Rationale assumes SCN8A-like mutation where levetiracetam is preferred, but this is not universally accurate— for SCN8A, sodium channel blockers like carbamazepine (C) are often effective first-line; valproic acid (A) risks behavioral worsening in ASD, consistent with guidelines, but item's implied logic overlooks gene-specific nuances and regional variations in therapy. Overall, vignette aligns with board-level epilepsy management but introduces inaccuracy by not specifying mutation. Minimal fix: Edit stem to specify 'de novo SCN8A mutation' to make B uniquely defensible and accurate.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-005", "question": "A 55-year-old man with Parkinson's disease develops sudden onset of dysarthria and hemiparesis. MRI shows acute infarction in the lenticulostriate territory, but vessel imaging is normal. Coagulation studies reveal an abnormality. What is the underlying mechanism?", "options": ["Cardioembolic stroke from atrial fibrillation", "Lacunar infarct due to small vessel disease", "Thrombotic stroke from antiphospholipid syndrome", "Vasculitis mimicking stroke", "Embolic stroke from levodopa-induced arrhythmia"], "answer": "C", "answer_index": 2, "explanation": "Antiphospholipid syndrome can cause thrombotic strokes in atypical territories without large vessel occlusion, especially with coagulation abnormalities. Lacunar infarcts are typically hypertensive, not matching this profile. Cardioembolism usually involves larger territories or arrhythmias, absent here.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Sudden dysarthria and hemiparesis in a 55-year-old man with Parkinson's disease; MRI showing acute lenticulostriate territory infarction with normal vessel imaging; abnormal coagulation studies. These clues point to a thrombotic mechanism from hypercoagulability (e.g., APS), as lenticulostriate infarct suggests small vessel involvement without large vessel occlusion, and coagulation abnormality discriminates against standard lacunar etiology.\\nMain logical issue(s), if any: None; the item supports C as the unique best, with alternatives inferior: A lacks arrhythmia evidence; B (lacunar) typically lacks coagulation issues and often requires hypertension (unstated but not contradicted); D has no inflammatory signs; E assumes unmentioned levodopa-induced arrhythmia.\\nMain medical accuracy issue(s), if any: Mostly accurate, but minor nuance: lenticulostriate territory is not 'atypical' for APS as stated in rationale (APS can cause lacunar-like infarcts); coagulation abnormality is vague without specifying tests (e.g., lupus anticoagulant), potentially allowing minor ambiguity, though it aligns with standard APS presentation in strokes without large vessel disease.\\nMinimal fix: Specify in stem: 'coagulation studies reveal prolonged PTT and positive lupus anticoagulant' to unambiguously confirm APS and eliminate any underspecification.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Sudden dysarthria and hemiparesis in a 55-year-old man with Parkinson's disease; MRI showing acute lenticulostriate territory infarction with normal vessel imaging; abnormal coagulation studies. These clues point to a thrombotic mechanism from hypercoagulability (e.g., APS), as lenticulostriate infarct suggests small vessel involvement without large vessel occlusion, and coagulation abnormality discriminates against standard lacunar etiology.\nMain logical issue(s), if any: None; the item supports C as the unique best, with alternatives inferior: A lacks arrhythmia evidence; B (lacunar) typically lacks coagulation issues and often requires hypertension (unstated but not contradicted); D has no inflammatory signs; E assumes unmentioned levodopa-induced arrhythmia.\nMain medical accuracy issue(s), if any: Mostly accurate, but minor nuance: lenticulostriate territory is not 'atypical' for APS as stated in rationale (APS can cause lacunar-like infarcts); coagulation abnormality is vague without specifying tests (e.g., lupus anticoagulant), potentially allowing minor ambiguity, though it aligns with standard APS presentation in strokes without large vessel disease.\nMinimal fix: Specify in stem: 'coagulation studies reveal prolonged PTT and positive lupus anticoagulant' to unambiguously confirm APS and eliminate any underspecification.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-006", "question": "In the ICU, a 70-year-old patient with septic shock from pneumonia remains hypotensive despite vasopressors and fluids. Adrenal function testing shows a blunted cortisol response, but random cortisol is normal. What is the next step in management?", "options": ["Initiate hydrocortisone replacement therapy", "Add fludrocortisone for mineralocorticoid support", "Perform cosyntropin stimulation test", "Switch to alternative vasopressor like vasopressin", "Administer ascorbic acid and thiamine"], "answer": "D", "answer_index": 3, "explanation": "Relative adrenal insufficiency in sepsis may not respond to steroids if cortisol is normal; switching to vasopressin addresses vasoplegia more effectively. Hydrocortisone is controversial without clear deficiency. Cosyntropin is already implied by blunted response.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (primary; secondary U leading to M). Verdict on keyed answer: Miskeyed. Key stem clues: 70-year-old with septic shock from pneumonia, persistent hypotension despite vasopressors and fluids, blunted cortisol response on adrenal function testing, normal random cortisol—these drive consideration of relative adrenal insufficiency (RAI) while not specifying current vasopressor type. Main logical issue(s): A unique best answer (A: hydrocortisone) is defensible based on blunted response implying RAI warranting steroid replacement, but the key (D) mismatches by prioritizing vasopressin without stem details justifying it over steroids; underspecification of vasopressor (e.g., norepinephrine vs. others) allows multiple defensible options (A and D) as next steps per guidelines. Main medical accuracy issue(s): Item relies on adrenal testing (blunted response) to guide management, contradicting SSC 2021 guidelines suggesting against ACTH stimulation testing and favoring empirical IV corticosteroids for refractory septic shock; rationale inaccurately deems hydrocortisone 'controversial' without 'clear deficiency' despite blunted response defining RAI, and overlooks vasopressin's role as adjunct to norepinephrine, not a switch. Minimal fix: Change keyed answer to A and add stem detail specifying 'despite norepinephrine' to disambiguate from D.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (primary; secondary U leading to M). Verdict on keyed answer: Miskeyed. Key stem clues: 70-year-old with septic shock from pneumonia, persistent hypotension despite vasopressors and fluids, blunted cortisol response on adrenal function testing, normal random cortisol—these drive consideration of relative adrenal insufficiency (RAI) while not specifying current vasopressor type. Main logical issue(s): A unique best answer (A: hydrocortisone) is defensible based on blunted response implying RAI warranting steroid replacement, but the key (D) mismatches by prioritizing vasopressin without stem details justifying it over steroids; underspecification of vasopressor (e.g., norepinephrine vs. others) allows multiple defensible options (A and D) as next steps per guidelines. Main medical accuracy issue(s): Item relies on adrenal testing (blunted response) to guide management, contradicting SSC 2021 guidelines suggesting against ACTH stimulation testing and favoring empirical IV corticosteroids for refractory septic shock; rationale inaccurately deems hydrocortisone 'controversial' without 'clear deficiency' despite blunted response defining RAI, and overlooks vasopressin's role as adjunct to norepinephrine, not a switch. Minimal fix: Change keyed answer to A and add stem detail specifying 'despite norepinephrine' to disambiguate from D.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-007", "question": "A 38-year-old woman with chronic myeloid leukemia on dasatinib develops pleural effusions and fatigue. Cytogenetic analysis shows additional clonal evolution. What is the most appropriate therapeutic adjustment?", "options": ["Switch to imatinib to reduce pulmonary toxicity", "Add interferon-alpha for immunomodulation", "Initiate ponatinib for resistant mutations", "Dose reduce dasatinib and monitor", "Proceed to allogeneic stem cell transplant"], "answer": "C", "answer_index": 2, "explanation": "Clonal evolution in CML on dasatinib often indicates T315I mutation, for which ponatinib is effective despite pulmonary risks. Imatinib lacks potency against advanced disease. Transplant is considered but not first-line without failure of second-generation TKIs.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the most appropriate therapeutic adjustment in a 38-year-old woman with CML on dasatinib presenting with pleural effusions, fatigue, and cytogenetic evidence of additional clonal evolution. Key stem clues include dasatinib-associated pleural effusions (toxicity), fatigue, and clonal evolution suggesting disease progression or accelerated phase, but lack mutation analysis, prior TKI history, or response details, failing to drive a unique best answer. Main logical issue: Multiple answers defensible (M)—C (ponatinib) assumes T315I resistance not stated in stem, while E (allogeneic transplant) is reasonable for young patient with accelerated-phase features per guidelines; underspecification (U) of critical details like BCR-ABL mutation status requires unstated assumptions for discrimination. Main medical accuracy issues: Rationale inaccurately equates cytogenetic clonal evolution with T315I mutation (they are distinct—clonal evolution involves additional chromosomal abnormalities, not necessarily point mutations); ponatinib is specifically indicated for T315I or multi-TKI failure, not generically for clonal evolution; imatinib switch wouldn't address advanced disease potency needs. Minimal fix: Add to stem 'mutation analysis confirms T315I mutation' to specify resistance mechanism, making C unambiguously best.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the most appropriate therapeutic adjustment in a 38-year-old woman with CML on dasatinib presenting with pleural effusions, fatigue, and cytogenetic evidence of additional clonal evolution. Key stem clues include dasatinib-associated pleural effusions (toxicity), fatigue, and clonal evolution suggesting disease progression or accelerated phase, but lack mutation analysis, prior TKI history, or response details, failing to drive a unique best answer. Main logical issue: Multiple answers defensible (M)—C (ponatinib) assumes T315I resistance not stated in stem, while E (allogeneic transplant) is reasonable for young patient with accelerated-phase features per guidelines; underspecification (U) of critical details like BCR-ABL mutation status requires unstated assumptions for discrimination. Main medical accuracy issues: Rationale inaccurately equates cytogenetic clonal evolution with T315I mutation (they are distinct—clonal evolution involves additional chromosomal abnormalities, not necessarily point mutations); ponatinib is specifically indicated for T315I or multi-TKI failure, not generically for clonal evolution; imatinib switch wouldn't address advanced disease potency needs. Minimal fix: Add to stem 'mutation analysis confirms T315I mutation' to specify resistance mechanism, making C unambiguously best.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-008", "question": "A 35-year-old woman in the emergency department collapses after ingesting an unknown substance. She has bradycardia, hypotension, and miosis. Atropine provides partial response, but symptoms recur. What is the definitive antidote?", "options": ["Pralidoxime for organophosphate poisoning", "N-acetylcysteine for acetaminophen", "Flumazenil for benzodiazepine overdose", "Physostigmine for anticholinergic toxicity", "Hydroxocobalamin for cyanide"], "answer": "A", "answer_index": 0, "explanation": "This cholinergic toxidrome suggests organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase after initial atropine. Atropine alone is insufficient for severe cases. Other antidotes target different mechanisms not fitting the presentation.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include collapse after unknown ingestion, bradycardia, hypotension, miosis (classic cholinergic toxidrome), partial atropine response with recurrence, implying need for definitive antidote beyond muscarinic blockade. These point to organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase. No main logical issues; stem allows discrimination without contradictions or underspecification, as symptoms uniquely fit organophosphates among options. No medical accuracy issues; aligns with current toxicology standards (e.g., ATSDR, ACMT guidelines) emphasizing pralidoxime post-atropine for severe cases. Alternatives are inferior: B (NAC) fits acetaminophen hepatotoxicity, absent here; C (flumazenil) for benzodiazepines causing CNS depression without cholinergic signs; D (physostigmine) for anticholinergics with opposite toxidrome (mydriasis, tachycardia); E (hydroxocobalamin) for cyanide with lactic acidosis, not miosis/bradycardia. Minimal fix: None needed, as item is unambiguous and accurate. The clinical problem asks for the definitive antidote in this toxidrome. Discriminating findings: positive (bradycardia, hypotension, miosis, atropine partial response); negative (no mention of other toxidromes like acidosis or mydriasis). Most likely diagnosis: organophosphate poisoning. Keyed answer fits without assumptions.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include collapse after unknown ingestion, bradycardia, hypotension, miosis (classic cholinergic toxidrome), partial atropine response with recurrence, implying need for definitive antidote beyond muscarinic blockade. These point to organophosphate poisoning, where pralidoxime regenerates acetylcholinesterase. No main logical issues; stem allows discrimination without contradictions or underspecification, as symptoms uniquely fit organophosphates among options. No medical accuracy issues; aligns with current toxicology standards (e.g., ATSDR, ACMT guidelines) emphasizing pralidoxime post-atropine for severe cases. Alternatives are inferior: B (NAC) fits acetaminophen hepatotoxicity, absent here; C (flumazenil) for benzodiazepines causing CNS depression without cholinergic signs; D (physostigmine) for anticholinergics with opposite toxidrome (mydriasis, tachycardia); E (hydroxocobalamin) for cyanide with lactic acidosis, not miosis/bradycardia. Minimal fix: None needed, as item is unambiguous and accurate. The clinical problem asks for the definitive antidote in this toxidrome. Discriminating findings: positive (bradycardia, hypotension, miosis, atropine partial response); negative (no mention of other toxidromes like acidosis or mydriasis). Most likely diagnosis: organophosphate poisoning. Keyed answer fits without assumptions.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-009", "question": "A 12-year-old girl with juvenile idiopathic arthritis on etanercept develops fever, rash, and lymphadenopathy. Serology is positive for a virus, but PCR on lymph node biopsy reveals clonal T-cell population. What is the most likely complication?", "options": ["Drug reaction with eosinophilia and systemic symptoms", "EBV-associated lymphoproliferative disorder", "Macrophage activation syndrome", "Secondary hemophagocytic lymphohistiocytosis", "TNF inhibitor-induced lymphoma"], "answer": "E", "answer_index": 4, "explanation": "TNF inhibitors like etanercept increase risk of T-cell lymphomas, especially with clonal populations on biopsy, beyond viral associations. EBV-LPD is B-cell predominant. MAS and HLH are cytokine-driven without clonality.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the most likely complication in a 12-year-old girl with JIA on etanercept presenting with fever, rash, lymphadenopathy, positive viral serology, and clonal T-cell population on lymph node biopsy. Key stem clues include etanercept use (TNF inhibitor), systemic symptoms, unspecified viral serology, and crucially, clonal T-cell population, pointing to T-cell lymphoma as a treatment-related risk, distinguishing from viral-driven or cytokine syndromes. These findings imply TNF inhibitor-associated lymphoma. The keyed answer E fits due to established lymphoma risk with TNF inhibitors, supported by clonal T-cell evidence; assumes viral serology is incidental or not causative of T-cell clonality. Alternatives: A (DRESS) lacks eosinophilia and clonality; B (EBV-LPD) specifies EBV not mentioned in stem and is typically B-cell; C (MAS) and D (secondary HLH) are cytokine-driven without clonal populations. Logical validity: Stem allows unique best answer E without contradictions or underspecification, as unspecified virus prevents B from being defensible. Medical accuracy: Consistent with guidelines on TNF inhibitor lymphoma risk (e.g., FDA warnings); no major errors, though viral role could be nuanced. Minimal fix: Change stem to 'Serology is positive for EBV' to clarify and prevent any perceived ambiguity around option B.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the most likely complication in a 12-year-old girl with JIA on etanercept presenting with fever, rash, lymphadenopathy, positive viral serology, and clonal T-cell population on lymph node biopsy. Key stem clues include etanercept use (TNF inhibitor), systemic symptoms, unspecified viral serology, and crucially, clonal T-cell population, pointing to T-cell lymphoma as a treatment-related risk, distinguishing from viral-driven or cytokine syndromes. These findings imply TNF inhibitor-associated lymphoma. The keyed answer E fits due to established lymphoma risk with TNF inhibitors, supported by clonal T-cell evidence; assumes viral serology is incidental or not causative of T-cell clonality. Alternatives: A (DRESS) lacks eosinophilia and clonality; B (EBV-LPD) specifies EBV not mentioned in stem and is typically B-cell; C (MAS) and D (secondary HLH) are cytokine-driven without clonal populations. Logical validity: Stem allows unique best answer E without contradictions or underspecification, as unspecified virus prevents B from being defensible. Medical accuracy: Consistent with guidelines on TNF inhibitor lymphoma risk (e.g., FDA warnings); no major errors, though viral role could be nuanced. Minimal fix: Change stem to 'Serology is positive for EBV' to clarify and prevent any perceived ambiguity around option B.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed125", "question_id": "20251201T041413890Z_grok-4-0709_seed125-010", "question": "A 68-year-old man with amyotrophic lateral sclerosis presents with progressive dysphagia and aspiration. Videofluoroscopy shows pharyngeal weakness. Non-invasive ventilation is in use. What is the most appropriate intervention?", "options": ["Percutaneous endoscopic gastrostomy placement", "Botulinum toxin injection into cricopharyngeus", "Tracheostomy for airway protection", "Speech therapy with swallowing exercises", "Pharmacologic enhancement with edrophonium"], "answer": "B", "answer_index": 1, "explanation": "In ALS with cricopharyngeal dysfunction causing dysphagia, botulinum toxin relaxes the muscle to improve swallowing, a targeted approach before invasive feeding. PEG is for nutrition but not dysphagia mechanism. Tracheostomy addresses ventilation, not swallowing.", "generator_model": "grok-4-0709", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U (secondary M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 68-year-old man with ALS, progressive dysphagia and aspiration, videofluoroscopy showing pharyngeal weakness, non-invasive ventilation in use; question seeks most appropriate intervention for dysphagia/aspiration. These clues suggest bulbar involvement in ALS but lack specificity on mechanism (e.g., no mention of cricopharyngeal hypertonicity or spasm), failing to drive a unique best answer. Main logical issue(s): Underspecified (U) as critical detail on type of pharyngeal dysfunction is missing, requiring unstated assumption for B; this leads to multiple defensible answers (M), with A (PEG for nutrition/aspiration prevention in severe cases), D (speech therapy as initial conservative management), and potentially B all reasonably arguable based on stem. Main medical accuracy issue(s): Keyed B (botulinum toxin) assumes cricopharyngeal dysfunction not stated in stem, which is inconsistent with standard ALS management where botox is reserved for documented upper esophageal sphincter hypertonicity; for general pharyngeal weakness, it risks worsening dysphagia, contradicting guidelines favoring speech therapy or PEG; edrophonium (E) is irrelevant to ALS. Minimal fix: Edit stem to add 'with cricopharyngeal hypertonicity' to videofluoroscopy findings, making B uniquely defensible and accurate.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (secondary M). Verdict on keyed answer: Not uniquely determinable. Key stem clues: 68-year-old man with ALS, progressive dysphagia and aspiration, videofluoroscopy showing pharyngeal weakness, non-invasive ventilation in use; question seeks most appropriate intervention for dysphagia/aspiration. These clues suggest bulbar involvement in ALS but lack specificity on mechanism (e.g., no mention of cricopharyngeal hypertonicity or spasm), failing to drive a unique best answer. Main logical issue(s): Underspecified (U) as critical detail on type of pharyngeal dysfunction is missing, requiring unstated assumption for B; this leads to multiple defensible answers (M), with A (PEG for nutrition/aspiration prevention in severe cases), D (speech therapy as initial conservative management), and potentially B all reasonably arguable based on stem. Main medical accuracy issue(s): Keyed B (botulinum toxin) assumes cricopharyngeal dysfunction not stated in stem, which is inconsistent with standard ALS management where botox is reserved for documented upper esophageal sphincter hypertonicity; for general pharyngeal weakness, it risks worsening dysphagia, contradicting guidelines favoring speech therapy or PEG; edrophonium (E) is irrelevant to ALS. Minimal fix: Edit stem to add 'with cricopharyngeal hypertonicity' to videofluoroscopy findings, making B uniquely defensible and accurate.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}]